Tisagenlecleucel is a type of CAR T-cell therapy that is composed of genetically modified T-cells from the patient, which are directed against CD19.
The drug is indicated for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia, adult patients with relapsed or refractory large B-cell lymphoma after therapy, diffuse large B-cell lymphoma, high grade B-cell lymphoma and follicular lymphoma.